Clinical trials: Advanced Solid Tumors Patients
Advanced Cancers
Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
The goal of this clinical research study is to learn if ilorasertib (ABT-348) can help to control CDKN2A-deficient cancer. CDKN2A deficiency is a type of mutation (a genetic change). The safety of this drug will also be studied.
- Trial name
- NCT02478320
- Testing
- Ilorasertib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045.
- Trial name
- NCT06056323
- Testing
- HB0045 Drug Product
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Malignant Melanoma, Advanced Solid Tumors
AMT-253 in Patients With Advanced Solid Tumours
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors.
- Trial name
- NCT06209580
- Testing
- AMT-253 for injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Multitude Therapeutics Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of combining alvocidib, irinotecan hydrochloride, and cisplatin in treating patients who have advanced solid tumors.
- Trial name
- NCT00046917
- Testing
- alvocidib, irinotecan hydrochloride, cisplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus expressing interferon beta in treating patients with liver cancer or solid tumors with lesions that have spread to other parts of…
- Trial name
- NCT01628640
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Breast Cancer, Ovarian Cancer
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- NCT06065059
- Testing
- TNG348, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Tango Therapeutics, Inc.
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of R-(-)-gossypol acetic acid when given together with cisplatin and etoposide in treating patients with advanced solid tumors or extensive stage small cell lung…
- Trial name
- NCT00544596
- Testing
- R-(-)-gossypol acetic acid, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of solid tumors by stopping blood flow to the tumor.
- Trial name
- NCT00005996
- Testing
- cisplatin, gemcitabine hydrochloride, semaxanib
- Sponsor
- Jonsson Comprehensive Cancer Center
Solid Tumours
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
The purpose of this study is to assess the effect of food on the pharmacokinetics (PK) of a single dose of AZD1775 (printed capsules) in patients with advanced solid tumours.
- Trial name
- NCT03315091
- Testing
- Treatment A - AZD1775 administered under fasted conditions, Treatment B - AZD1775 administered under fed conditions.
- Where
- 7 sites in France, Netherlands and 1 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Solid Tumor
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.
- Trial name
- NCT01170897
- Testing
- PEGPH20
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Halozyme Therapeutics
Solid Tumors
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
To find the recommended dose of TROP2- CAR-NK cells that can be given to participants with advanced forms of solid tumors.
- Trial name
- NCT06066424
- Testing
- Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Study of Oral PQR309 in Patients With Advanced Solid Tumors
This is an open-label, multi-center, non-randomized, dose escalation Phase 1 study evaluating safety, tolerability, PK (pharmacokinetics) and efficacy of PQR309 in the treatment of selected patients with advanced solid tumors.
- Trial name
- NCT02483858
- Testing
- PQR 309
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- PIQUR Therapeutics AG
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Solid Tumor Malignancies
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C.
- Trial name
- NCT01924689
- Testing
- Clostridium novyi-NT spores
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- BioMed Valley Discoveries, Inc
Advanced Solid Tumor
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
To evaluate the efficacy and safety of LTC004 in combination with Toripalimab in 10 patients with advanced solid tumors resistant to first-line immunotherapy, all eligible subjects will receive LTC004 on day 1 of Week 1 and day 1…
- Trial name
- NCT06490068
- Testing
- LTC004+Toripalimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumor
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of autologous B4T2-001 CAR-T in subjects with advanced solid tumors including but not…
- Trial name
- NCT06072989
- Testing
- B4T2-001 autologous CAR-T
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai East Hospital
Advanced or Metastatic Solid Tumors
A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS012 monotherapy and combination with chemotherapy in patients with Advanced or Metastatic Solid Tumors.
- Trial name
- NCT05388279
- Testing
- JS012, JS012 combine with chemotherapy
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.